Neurocrine Biosciences, Inc.
513 articles with Neurocrine Biosciences, Inc.
-
U.S. Food and Drug Administration(FDA) has granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
-
Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
5/12/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation.
-
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
5/4/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2022.
-
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
5/3/2022
Neurocrine Biosciences, Inc. will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time on Tuesday, May 10, 2022 in Las Vegas.
-
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results
4/13/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 4, 2022.
-
Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022
4/1/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced results from the Phase 3 KINECT-HD study, which demonstrated once-daily administration of valbenazine was associated with significant improvement in chorea associated with Huntington disease (HD) compared with placebo.
-
Neurocrine has noticed some positive results of valbenazine for treating Huntington's diseases related chorea. Here's all about what they found in the study.
-
Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
3/28/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare on March 28, 2022.
-
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
3/28/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) at the Academy of Managed Care Pharmacy (AMCP) 2022 annual meeting in Chicago on March 29–April 1.
-
Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
3/24/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders program and telemedicine research at the American Academy of Neurology (AAN) Annual Meeting being held in person April 2–7, 2022 in Seattle and virtually April 24–26.
-
Neurocrine Biosciences to Present at Stifel 2022 CNS Days
3/21/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2022 CNS Days virtual conference at 3:30 p.m. Eastern Time on Monday, March 28, 2022.
-
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences - Mar 01, 2022
3/1/2022
Neurocrine Biosciences, Inc. announced that members of the management team will participate at the following investor conferences.
-
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022
2/11/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided financial guidance for 2022.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results
1/25/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on Friday, February 11, 2022.
-
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
1/12/2022
Xenon Pharmaceuticals Inc. today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon.
-
Biopharma companies are building momentum to carry them through the bulk of 2022. BioSpace takes a look at some of the recent announcements.
-
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones
1/6/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product sales results of INGREZZA® (valbenazine) for 2021, and key clinical development milestones for 2022 and 2023.
-
Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Neurocrine Biosciences, Inc. will present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Eastern Time on Monday Jan. 10, 2022.
-
Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
12/23/2021
Sosei Group Corporation announces that in connection with the Collaboration and License Agreement with Neurocrine Biosciences, Inc. announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on 22 December 2021.
-
Neurocrine Biosciences and Acadia Pharmaceuticals posted positive top-line results from their respective Phase III trials on major neurological diseases.